Figure 2. Deletion of Regnase-1 enhances efficacy of ACT against solid and blood cancers.
OT-I (a, b), pmel-1 (c, d) or CD8+ CAR-T (e, f) cells (5 × 106) transduced with non-targeting control sgRNA or sgRegnase-1 were transferred into mice at day 12 after B16-Ova (a, b) or B16-F10 (c, d) melanoma engraftment, or at day 7 after Ph+ B-ALL cell engraftment (e, f), followed by analyses of tumor size (a, c), mouse survival (b, d, e) and tumor burden via Xenogen imaging of bioluminescent signal intensities (f). Non-treatment control mice received no T cell transfer. *P < 0.05; **P < 0.01; ***P < 0.001; two-way ANOVA in a, c, and Log-rank (Mantel-Cox) test in b, d, e. Data are representative of two (a, b, e, f) or four (c, d) independent experiments.